Buffett Slams Healthcare Overload: Why Eli Lilly Alone Won't Save You

Well, hello there. I just poured myself a tall glass of Cherry Coke, put on my reading glasses, and took a look at your holdings. Looking at this statement, I have to ask—are you an investor, or are you trying to open your own hospital?

Charlie Munger used to say that if you’re going to invest in something, you better understand exactly how it makes money. It seems you’ve taken that to heart, provided the only thing you understand is pills, surgical robots, and health insurance. We always say to invest within your circle of competence, but my goodness, you’ve locked yourself inside a pharmacy and swallowed the key! There is a fine line between a focused portfolio and betting your entire net worth on the FDA’s mood on any given Tuesday. Let’s look under the microscope and see if you’ve got a margin of safety here, or if you’re just chasing the latest medical miracles.

Let’s start with the big picture. Your sector breakdown is downright staggering: roughly 86% of your money is tied up in the healthcare sector. Even your broad market allocation, which sits at 8.5%, is just a healthcare ETF! Geographically, you're heavy on North America at nearly 74%, with the rest mostly in Europe.

Now, I will give you credit where it is due: you are buying businesses with real, durable competitive advantages. Over 56% of your portfolio benefits from intangible assets like patents and strong brands, and another 20% enjoys high switching costs. Companies like UnitedHealth Group—which makes up 9.3% of your portfolio—have a magnificent scale advantage. I love a business with a wide moat.

But you’ve also caught the growth bug. Nearly 54% of your strategy is allocated to growth. You have 11.4% sitting in Eli Lilly and 10.7% in Novo Nordisk. These are wonderful businesses—truly wonderful—but a wonderful business can become a terrible investment if you pay too much for it. You’re betting over a fifth of your net worth on the GLP-1 weight-loss craze.

And then there's your cash reserve. At just 3.5%, you're running on fumes. At Berkshire, we always keep a mountain of cash. Cash is king only when you deploy it, sure, but if Mr. Market gets depressed tomorrow and puts great businesses on sale, you’ll be standing there with empty pockets. A 3.5% reserve gives you absolutely no dry powder.

🚩 Lethal Sector Concentration: Putting 86% of your money into healthcare isn't investing; it's a thematic crusade. Healthcare is incredibly sensitive to political winds, patent cliffs, and regulatory approvals. If Washington decides to cap drug prices or alter insurance models, this entire portfolio catches a severe cold at the exact same time.

🚩 Chasing Momentum Without a Margin of Safety: Eli Lilly and Novo Nordisk are great companies, but Wall Street has priced them for absolute perfection. Paying astronomical multiples for growth leaves you with zero margin of safety. If their pipeline hits a snag, the drop will be steep.

🚩 Speculative Gambling: I see you've got 3.4% in Moderna and 2.1% in a pre-IPO biotech startup. Charlie would have called that "rat poison." Biotech startups have binary outcomes—they either hit a home run with a drug trial or they go to zero. We don't play the lottery at Berkshire.

🚩 No Dry Powder: With only 3.5% in cash, you have no flexibility. When it rains gold, you want to reach for a bucket, not a thimble. Your thimble is currently full of lint.

I have to give this portfolio a 4.5 out of 10. You have excellent taste in high-quality companies with wide moats, but your portfolio construction is dangerously lopsided, and you're paying premium prices for popular trends.

Here is what I would humbly suggest you do:

1. Build Your Cash Reserves: Stop buying for a while and let some dividends or fresh capital build your cash position up to at least 10-15%. You need ammunition for when the market inevitably misprices a good business.

2. Step Outside the Pharmacy: Broaden your circle of competence. Look for boring, wonderful businesses in consumer staples, financials, or industrials to offset this massive regulatory risk.

3. Assess Your Margin of Safety: Look closely at the valuations of your biggest growth holdings. If you are relying on heroic future assumptions to justify today's price, it might be time to trim the fat.

4. Drop the Speculation: Leave the pre-IPO biotech gambles to the venture capitalists. Stick to businesses that actually generate predictable, growing cash flows today.

Always remember: "Diversification is protection against ignorance. It makes little sense if you know what you are doing." But unless your last name is Mayo and you run a clinic, nobody knows enough about one sector to risk 86% of their wealth on it. Invest wisely!